The biotechnology industry's main trade group is making the case that the issues shaping its future shouldn't be handled in separate silos.
According to geneonline.com, John F. Crowley, the chief executive of BIO, is pushing to fold regulation, artificial intelligence, and national security into what the outlet describes as a single "competitiveness agenda" for the biotech sector.
The framing is notable. Historically, drug developers have treated regulatory policy, emerging technology, and security concerns as distinct conversations with different audiences in Washington. Crowley's pitch, as reported by geneonline.com, is to treat them as one connected story about whether the United States stays ahead in biotechnology.
Artificial intelligence sits at the center of that argument. AI is increasingly used in tasks like drug discovery and research, which means the rules governing it overlap with how quickly and competitively biotech companies can operate. Linking AI to national security reflects a broader Washington trend of framing advanced technology as a strategic asset, not just a commercial one.
The source item is a single report and does not include specific policy proposals, figures, or timelines beyond Crowley's unifying message.
Why it matters: how an industry frames its priorities shapes the laws it gets. If biotech successfully bundles AI oversight, drug regulation, and security under one "competitiveness" banner, it could influence how aggressively—or cautiously—governments choose to regulate AI in medicine.